CYP26A1 and acute promyelocytic leukemia: Similarly, stromal-dependent CYP26 activity protects APL and non-APL blasts from pharmacological levels of ATRA and, thus, may contribute to the persistence of MRD in patients treated with single-agent ATRA [88,89].